The abstract is read at the publisher; the summary is JClub's.
YTHDC1 is upregulated in multiple myeloma cells and is linked to poor prognosis, where it promotes m6A-dependent tumor cell growth and survival.
- Why it matters: The contribution of m6A regulation to multiple myeloma pathogenesis is unclear, despite evidence that m6A modifier dysregulation can support tumorigenesis in other contexts.
- What they did: The study mapped YTHDC1 function in MM cells, showing it binds m6A-modified EP300 mRNA to increase EP300 stability and expression, while p300 activates YTHDC1 transcription via H3K27ac deposition and IRF3/IRF4 recruitment.
- The result: A self-reinforcing YTHDC1–EP300 loop between RNA m6A methylation and H3K27 acetylation is implicated in MM pathogenesis, supporting the YTHDC1-EP300 axis as a therapeutic target.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.